Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.
Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
Most people who received Rubraca maintenance therapy experienced tumor regression or had stable disease.
A recent study found that 42% of patients depleted 100 percent of their assets—an average loss of $92,000—within two years of diagnosis.
PARP inhibitor demonstrates unprecedented improvement in progression-free survival.
Immunotherapy led to better outcomes for patients with inoperable non-small-cell lung cancer.
Study shows eight-month survival advantage for those not previously treated with chemotherapy.
Lynparza is now indicated for breast cancer patients with BRCA mutations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.